Fundraising Fox
/Companies
Sign in

20/20 GeneSystems

Gaithersburg, US · 1 known investors

Find your way into 20/20 GeneSystems

Sign up to find every way you can get introduced to 20/20 GeneSystems

  • Your email: who you already know at 20/20 GeneSystems, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 20/20 GeneSystems team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.

AI & Machine LearningBiotechDigital Health

Founders & leadership

JC
Jonathan CohenPresident & CEO, founderExecutive Officer, Director at 2020Gene
MC
Mr. CohenFounder, CEO & President
AS
Anne ShiflettExecutive
JZ
Jiminy ZhouExecutive
DL
Dr. LebowitzChief Scientific Officer
MB
Mr. BergmanChief Financial Officer

Board

JK
Joel KanterBoard director
PR
Prasanth ReddyBoard director
JG
John G ComptonBoard director
JW
John W. RollinsBoard director
WL
Wei LuBoard director
RM
Richard M. CohenBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 3 rounds · 2014–2025

▶$70KraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan CohenExecutive Officer, Director
  • Prasanth ReddyDirector
  • John G ComptonDirector
  • John W. RollinsDirector
  • Wei LuDirector
  • Richard M. CohenDirector
  • Anne ShiflettExecutive Officer
  • Jiminy ZhouExecutive Officer
  • Michael A RossDirector
Offering amount
$3M
Amount sold
$70K
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedFeb 2016 · 66 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Jonathan CohenExecutive Officer, Director
  • Caroline PopperDirector
  • Dean HautamakiDirector
  • Vladimir KnezevicDirector
  • Donald WallachDirector
  • Joel KanterExecutive Officer, Director
Offering amount
$4M
Amount sold
$2.5M
Minimum investment
$5K
Sales commissions
$37.1K
Placement agents
LBMZ Securities, Inc.
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vladimir KnezevicDirector
  • Caroline PopperDirector
  • Joel KanterExecutive Officer, Director
  • Donald WallachDirector
  • Jonathan CohenExecutive Officer, Director
  • Dean HautamakiDirector
Offering amount
$3M
Amount sold
$2M
Minimum investment
$50K
Proceeds to insiders
$150K
First sale
Jan 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 17 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2014$750K
National Institutes of Health (NIH)National Institutes of HealthPhase II2010$2.8M
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$199.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$217.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$183.9K
National Institutes of Health (NIH)National Institutes of HealthPhase II2008$649.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2007$165.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2007$117.9K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2006$177.3K
National Institutes of Health (NIH)National Institutes of HealthPhase I2006$177.3K
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2004$100K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$100K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$99.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$96.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$96.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2004$79.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2003$97.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does 20/20 GeneSystems do?
20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.
Who founded 20/20 GeneSystems?
20/20 GeneSystems was founded by Jonathan Cohen, Mr. Cohen.
Who are 20/20 GeneSystems's investors?
20/20 GeneSystems's investors include Keiretsu Forum.
How much funding has 20/20 GeneSystems raised?
20/20 GeneSystems has disclosed $4.6M raised across 3 rounds.
Where is 20/20 GeneSystems headquartered?
20/20 GeneSystems is headquartered in Gaithersburg, US.